Genome Publications
https://doi.org/10.61096/ 978-81-981372-2-7_4

Chapter 4

Pain Pathways and Analgesic Innovation

Dr. Sridevi Pingali
Professor and Head, Department of Pharmaceutical Analysis,
Sri Venkateshwara college of Pharmacy, Madhapur, Hyderabad

Kukkala Prasanna
Assistant Professor, Department of Pharmaceutics,
Anurag Pharmacy College, Ananthagiri, Kodad, Suryapet Dt, Telangana, 508206.

Abstract: Pain, a multifaceted sensory and emotional experience, can arise from nociceptive, inflammatory, or neuropathic origins. The understanding of pain pathways has significantly evolved, revealing a complex interplay of peripheral and central sensitization mechanisms mediated by neurotransmitters such as prostaglandins, bradykinin, substance P, and glutamate. This chapter provides a comprehensive overview of current and emerging pharmacological approaches to pain management. It details the use of NSAIDs with emphasis on COX selectivity and associated risks, as well as opioid pharmacodynamics and strategies to reduce dependence. Therapies for neuropathic pain including gabapentinoids, antidepressants, and sodium channel blockers are explored in depth. Novel targets like TRPV1, CGRP, and Nav1.7, as well as monoclonal antibodies and gene therapy interventions, demonstrate the shift toward precision and biologic-based therapeutics. The chapter also highlights RNA-based modulation and clinical trials involving siRNA and CRISPR technologies for pain gene silencing. Non-pharmacological strategies such as neuromodulation, TENS, and cognitive-behavioral interventions are included as adjuncts to pharmacologic care. Finally, pharmacogenetic profiling for enzymes like CYP2D6 is reviewed for its role in personalized analgesia and risk mitigation. By integrating molecular insights, clinical relevance, and future directions, this chapter equips healthcare professionals with a nuanced understanding of analgesic innovation tailored to diverse pain mechanisms.

Keywords: Pain pathways, NSAIDs, Opioid analgesics, Neuropathic pain, TRPV1 inhibitors.

Citation: Sridevi Pingali, Kukkala Prasanna. Pain Pathways and Analgesic Innovation. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems.* 2025; Pp29-37. https://doi.org/10.61096/978-81-981372-2-7_4

4.0 INTRODUCTION

Pain is a complex physiological and psychological experience that serves as a protective mechanism against potential or actual tissue damage. It is broadly categorized into three types: nociceptive, neuropathic, and inflammatory pain. Nociceptive pain arises from direct activation of nociceptors in response to tissue injury or noxious stimuli, whereas neuropathic pain results from damage or dysfunction in the peripheral or central nervous system. Inflammatory pain emerges due to the sensitization of nociceptors from mediators such as cytokines, prostaglandins, and chemokines released during inflammation [1].

Effective pain management remains a significant clinical challenge, particularly in cases involving chronic pain syndromes such as fibromyalgia, diabetic neuropathy, or cancer-related pain. The long-term use of conventional analgesics like NSAIDs and opioids is frequently limited by adverse effects, tolerance, dependence, and risk of misuse [2]. Moreover, inter-individual variability in analgesic response and metabolism has necessitated a shift toward personalized pain therapy.

Recent advances have expanded our understanding of pain mechanisms at the molecular level, uncovering novel targets for pharmacologic intervention, including ion channels, neuropeptides, and pro-inflammatory cytokines. Biologic agents, gene-editing technologies, and neuromodulation therapies represent the forefront of innovative pain therapeutics. This chapter discusses the pathophysiological basis of pain, explores contemporary analgesic classes, and examines emerging innovations in the pharmacologic and non-pharmacologic management of pain.

4.1 Molecular Mechanisms of Pain

Pain perception begins at the peripheral terminals of nociceptors, specialized sensory neurons that respond to mechanical, thermal, or chemical stimuli. Activation of nociceptors leads to the release of various chemical mediators including prostaglandins, bradykinin, substance P, and glutamate, which initiate and amplify pain signals [3]. These mediators activate G-protein-coupled receptors and ion channels such as TRPV1, ASICs, and Nav1.7, resulting in depolarization and transmission of signals to the spinal cord.

At the spinal level, glutamate and substance P are key excitatory neurotransmitters that act on NMDA and NK1 receptors, respectively, facilitating synaptic transmission to second-order neurons. The phenomenon of central sensitization a state of heightened responsiveness of nociceptive neurons in the CNS is a hallmark of chronic pain conditions and is often maintained by persistent stimulation and glial activation [4].

Peripheral sensitization, on the other hand, is characterized by lowered thresholds and increased responsiveness of nociceptors due to the upregulation of receptors and ion channels, particularly in the presence of inflammatory mediators like IL-1β, TNF-α, and PGE2 [5]. This results in phenomena such as hyperalgesia (exaggerated response to painful stimuli) and allodynia (pain from non-painful stimuli).

The descending modulatory system, originating from the brainstem (e.g., periaqueductal gray, rostral ventromedial medulla), plays a pivotal role in modulating pain. It can exert both inhibitory and facilitatory effects through pathways involving serotonin, norepinephrine, and endogenous opioids [6]. Disruption of this balance contributes to the persistence of chronic pain.

Recent transcriptomic studies have revealed novel pain-related genes and targets, including microRNAs and epigenetic regulators, that modulate nociceptive processing and could serve as

therapeutic avenues [7]. The integration of such molecular insights with clinical data is essential for developing more precise and individualized approaches to pain management.

4.2 NSAIDs and COX Inhibitors

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a cornerstone in the management of nociceptive and inflammatory pain. Their analgesic, antipyretic, and anti-inflammatory properties stem primarily from the inhibition of cyclooxygenase (COX) enzymes, which catalyze the conversion of arachidonic acid into prostaglandins. These lipid mediators sensitize nociceptors and promote inflammation [8].

NSAIDs are classified based on their selectivity for COX-1 or COX-2 isoforms. COX-1 is constitutively expressed and involved in gastrointestinal (GI) protection, renal perfusion, and platelet aggregation, whereas COX-2 is inducible and upregulated during inflammation. Non-selective NSAIDs (e.g., ibuprofen, naproxen) inhibit both isoforms, while COX-2 selective inhibitors (e.g., celecoxib) were developed to minimize GI toxicity [9].

Despite their efficacy, NSAIDs are associated with significant adverse effects. GI complications, such as peptic ulcers and bleeding, result from COX-1 inhibition and decreased mucosal protection. Renal dysfunction may occur due to impaired renal prostaglandin synthesis, especially in patients with compromised volume status. Additionally, COX-2 inhibitors have been linked to cardiovascular (CV) risks, including increased incidence of myocardial infarction and stroke, attributed to the imbalance between prostacyclin and thromboxane A2 [10].

Current guidelines advocate for the lowest effective dose for the shortest duration to minimize toxicity, and the concomitant use of gastroprotective agents (e.g., proton pump inhibitors) in high-risk patients. Newer NSAIDs under development focus on dual inhibitors (e.g., COX/LOX) and NO-releasing NSAIDs that aim to retain efficacy while reducing adverse effects [11].

4.3 Opioid Analgesics

Opioid analgesics remain the most effective pharmacologic agents for the management of moderate-to-severe acute and chronic pain, particularly in oncologic and postoperative settings. Their action is mediated by binding to opioid receptors primarily μ (mu), but also κ (kappa) and δ (delta) receptors located in the brain, spinal cord, and peripheral tissues [12].

The μ-opioid receptor (MOR) is responsible for the analgesic effects as well as adverse effects including respiratory depression, euphoria, constipation, and dependence. Commonly used opioids include morphine, fentanyl, oxycodone, and hydromorphone, each differing in potency, receptor affinity, and pharmacokinetics [13].

One of the major challenges in opioid therapy is the development of tolerance, which necessitates higher doses to achieve the same analgesic effect, and physical dependence, which may result in withdrawal symptoms upon cessation. Moreover, the ongoing opioid crisis has highlighted the risk of opioid misuse, addiction, and overdose, particularly with long-term use and in susceptible populations [14].

To address these concerns, opioid-sparing strategies are being emphasized, including the use of multimodal analgesia, non-opioid adjuvants, and regional anesthetic techniques. New agents such as biased agonists (e.g., oliceridine) that preferentially activate analgesic pathways while minimizing adverse effects are under investigation [15].

Pharmacogenetic variability, especially polymorphisms in CYP2D6, can significantly impact opioid metabolism and efficacy. For instance, ultrarapid metabolizers may convert codeine to morphine at higher-than-expected rates, increasing the risk of toxicity, whereas poor metabolizers may receive inadequate analgesia [16].

Clinical guidelines now recommend risk stratification tools (e.g., ORT, SOAPP) and opioid treatment agreements to mitigate misuse. Integration of prescription drug monitoring programs (PDMPs) and naloxone co-prescribing further enhances the safety profile of opioid therapy [17].

4.4 Neuropathic Pain Agents

Neuropathic pain arises from damage or dysfunction of the somatosensory system and is often chronic, debilitating, and resistant to conventional analgesics like NSAIDs or opioids. Common conditions include diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury-related pain. Pharmacologic treatment targets aberrant neuronal excitability, neurotransmitter imbalance, and central sensitization [18].

Gabapentinoids, such as gabapentin and pregabalin, bind to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. These agents are first-line for many neuropathic conditions due to their efficacy and tolerable side effect profile, although sedation and dizziness are common [19].

Antidepressants, particularly tricyclic antidepressants (TCAs) like amitriptyline, and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine, are also widely used. They modulate descending inhibitory pain pathways by increasing synaptic serotonin and norepinephrine. Among these, duloxetine has demonstrated substantial benefit in diabetic neuropathy and fibromyalgia [20].

Sodium channel blockers, including carbamazepine, oxcarbazepine, and newer agents like lacosamide, inhibit neuronal hyperexcitability, particularly in trigeminal neuralgia and focal seizure-related pain syndromes [21]. Emerging therapies such as selective Nav1.7 inhibitors are under investigation, based on genetic studies linking Nav1.7 mutations to congenital insensitivity to pain [22].

Despite their effectiveness, many neuropathic pain agents require titration and individualized dosing to balance efficacy with adverse effects. Combining drugs with different mechanisms, along with non-pharmacological strategies, often yields better outcomes.

4.5 Targeting TRPV1, CGRP, and Nav1.7

Recent innovations in pain pharmacology have focused on non-opioid molecular targets, notably TRPV1, CGRP, and Nav1.7 key players in pain transmission and modulation.

Transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel activated by heat, capsaicin, and protons, expressed predominantly in nociceptive neurons. TRPV1 antagonists demonstrated efficacy in animal models; however, clinical translation has been limited due to hyperthermia-related side effects [23]. Current efforts are exploring peripherally restricted TRPV1 blockers to minimize central toxicity [24].

Calcitonin gene-related peptide (CGRP) is a neuropeptide involved in migraine pathophysiology, vasodilation, and neurogenic inflammation. Monoclonal antibodies targeting CGRP (e.g., erenumab, fremanezumab) and small-molecule CGRP receptor antagonists (gepants) have

revolutionized chronic migraine management by reducing attack frequency with minimal central side effects [25].

Nav1.7, a voltage-gated sodium channel subtype, is heavily implicated in pain signaling. Gain-of-function mutations in SCN9A (which encodes Nav1.7) cause inherited erythromelalgia, while loss-of-function mutations lead to congenital insensitivity to pain. These findings have spurred the development of highly selective Nav1.7 inhibitors, aiming to achieve effective analgesia without affecting normal sensation or motor function [26].

These novel pathways offer targeted and mechanism-specific pain relief, representing a paradigm shift in analgesic innovation. Ongoing clinical trials are evaluating their safety and efficacy in various pain phenotypes, including migraine, neuropathy, and visceral pain syndromes.

4.6 Biologics and Monoclonal Antibodies

Biologics and monoclonal antibodies (mAbs) have emerged as potent agents in target-specific pain modulation, especially for inflammatory and migraine-related pain conditions. These agents offer high specificity and prolonged duration of action, revolutionizing the landscape of chronic pain therapeutics.

One of the most successful applications is in the treatment of migraine via CGRP-targeted monoclonal antibodies. Agents such as erenumab (targets the CGRP receptor), and fremanezumab, galcanezumab, and eptinezumab (target CGRP ligand) have demonstrated efficacy in reducing migraine frequency and severity with favorable safety profiles [27]. These therapies bypass the need for daily dosing and have become vital options for patients with treatment-resistant or frequent episodic migraines.

In inflammatory pain syndromes, interleukin-1β (IL-1β) plays a critical role in sensitization and peripheral inflammation. Canakinumab, an IL-1β monoclonal antibody, has shown promise in autoimmune and chronic pain disorders, such as gout and rheumatoid arthritis, although its role in broader pain management is still under exploration [28].

Other mAb targets include nerve growth factor (NGF), a key modulator of nociceptive transmission. Anti-NGF antibodies (e.g., tanezumab) have demonstrated significant analgesic effects in osteoarthritis and chronic low back pain, though concerns about rapid joint degeneration and safety have hindered widespread use [29].

Despite their promise, the use of biologics in pain therapy requires long-term safety data, cost-benefit evaluations, and careful patient selection to optimize outcomes while avoiding immunogenicity or systemic immune suppression [30].

4.7 Gene Therapy and RNA-Based Pain Modulation

Gene therapy represents a frontier in precision pain medicine, offering long-lasting, potentially curative interventions by altering gene expression in pain pathways. Unlike traditional drugs that provide symptomatic relief, gene therapies aim to correct or silence pain-related genetic abnormalities at their source.

Small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) can inhibit the translation of pain-related genes, such as Nav1.7, TRPV1, and P2X3 receptors. Preclinical studies have demonstrated that intrathecal delivery of these agents can significantly reduce hyperalgesia and allodynia in models of neuropathic pain [31].

CRISPR/Cas9 gene editing allows for permanent disruption or correction of faulty genes. While its use in pain therapy is still in early-stage research, animal studies have shown sustained analgesia after in vivo CRISPR targeting of Nav1.7 in sensory neurons, supporting the feasibility of this approach [32].

Several gene therapy platforms are under clinical investigation. For example, HSV vector-based delivery of genes encoding enkephalins or GABAergic modulators directly into dorsal root ganglia has shown efficacy in reducing chronic pain in Phase I/II trials, with minimal adverse effects [33].

Challenges to widespread implementation include vector safety, immune response, target specificity, and regulatory hurdles. However, as delivery technologies and genomic editing tools advance, gene therapy holds transformative potential in chronic and intractable pain management, particularly where conventional treatments fail [34].

4.8 Non-Pharmacological Adjuncts

Non-pharmacological therapies are increasingly recognized as integral components of multimodal pain management, especially for chronic pain conditions where pharmacologic options alone may be insufficient or carry long-term risks. These approaches target both peripheral and central mechanisms of pain and are often used as adjuncts or alternatives to drugs.

Neuromodulation techniques, including spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation, deliver electrical impulses to modulate pain signaling at the spinal level. These methods are effective in complex regional pain syndrome, failed back surgery syndrome, and neuropathic pain. Recent advances include high-frequency SCS and closed-loop systems offering improved pain relief and patient satisfaction [35].

Transcutaneous electrical nerve stimulation (TENS) is a non-invasive method that stimulates peripheral nerves via skin electrodes. It is effective in musculoskeletal pain, diabetic neuropathy, and fibromyalgia. Although the mechanism is not fully understood, it likely involves gate control theory and endorphin release [36].

Behavioral interventions, such as cognitive-behavioral therapy (CBT), biofeedback, and mindfulness-based stress reduction, aim to alter pain perception, improve coping skills, and reduce psychological comorbidity such as anxiety and depression. These methods are particularly beneficial in chronic pain patients with overlapping mood disorders [37].

Other complementary strategies include acupuncture, yoga, aerobic exercise, and physiotherapy, which offer individualized pain relief with minimal side effects. While these methods may not replace pharmacologic treatment, their synergistic role in reducing pain intensity and improving quality of life is increasingly supported by clinical guidelines [38].

4.9 Personalized Analgesia and Pharmacogenetics

Interindividual variability in analgesic response and adverse effect profiles is a major challenge in pain management. Pharmacogenetics the study of how genetic differences influence drug metabolism and efficacy offers a path toward personalized analgesia, improving outcomes while reducing harm.

One of the most studied enzymes in this context is CYP2D6, which metabolizes many opioids such as codeine, tramadol, and hydrocodone. Poor metabolizers may experience insufficient

analgesia, whereas ultra-rapid metabolizers are at risk of opioid toxicity, including respiratory depression [39]. Genetic testing for CYP2D6 variants is now recommended in select patient populations to guide opioid prescribing.

Variants in OPRM1, the gene encoding the μ-opioid receptor, have also been linked to differences in opioid binding affinity and efficacy. The A118G polymorphism, for instance, may require dose adjustments or alternative therapies in patients with inadequate response [40].

Pharmacogenetic considerations extend to NSAIDs, where CYP2C9 polymorphisms affect metabolism of celecoxib and other COX-2 inhibitors, influencing both efficacy and gastrointestinal risk [41].

Advanced risk stratification tools incorporating genetic, behavioral, and clinical data are being developed to predict opioid misuse, overdose risk, and treatment response. Combining these tools with electronic health records and decision support systems can help optimize prescribing practices [42].

As testing becomes more accessible, integrating pharmacogenetics into routine pain management holds promise for achieving the goal of precision analgesia: tailoring the right drug, at the right dose, for the right patient.

4.10 CONCLUSION

This chapter presents a comprehensive exploration of the evolving landscape of pain management, emphasizing a transition from traditional analgesics to mechanism-based, personalized, and precision-targeted therapies. It underscores the complexity of pain, which arises through distinct molecular and neural mechanisms nociceptive, inflammatory, and neuropathic and the corresponding need for tailored interventions.

Conventional analgesics like NSAIDs and opioids, though widely used, come with significant safety and efficacy limitations. Therefore, the chapter highlights advances in understanding pain pathways that have led to novel therapeutic targets such as TRPV1, CGRP, and Nav1.7. These breakthroughs are supported by the development of monoclonal antibodies, gene therapies, RNA-based modulators, and cutting-edge delivery platforms.

Moreover, the role of pharmacogenetics and personalized medicine is emphasized for optimizing analgesic response and minimizing adverse effects. Non-pharmacological interventions like neuromodulation, cognitive-behavioral therapy, and TENS are validated as valuable adjuncts in holistic pain management.

In conclusion, the future of pain therapy lies in integrating molecular insights, technological innovation, and individualized treatment approaches to achieve safer, more effective, and durable pain relief across diverse patient populations.

REFERENCES

1. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–15.
2. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413(6852):203–10.
3. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A):2S–8S.

4. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018. p. 671–716.
5. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17(6):275–342.
6. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians guidelines. Pain Physician. 2008;11(2 Suppl):S5–62.
7. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing. Pain Physician. 2012;15(3 Suppl):S1–65.
8. Bannister K, Dickenson AH. What do monoamines do in pain modulation? Curr Opin Support Palliat Care. 2016;10(2):143–8.
9. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain. Eur J Neurol. 2010;17(9):1113–e88.
10. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence-based proposal. Pain. 2005;118(3):289–305.
11. Szallasi A, Sheta M, Targeting TRPV1 for pain relief. Mol Pain. 2012;8:70.
12. Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58 Suppl 1:33–47.
13. Emery EC, Luiz AP, Wood JN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets. 2016;20(8):975–83.
14. Dodick DW. CGRP monoclonal antibodies for the preventive treatment of migraine. Lancet Neurol. 2018;17(6):455–63.
15. Tepper SJ. History and review of anti-CGRP monoclonal antibodies for migraine. Headache. 2018;58(Suppl 1):238–75.
16. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27.
17. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521–31.
18. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: achievements and challenges. Expert Opin Investig Drugs. 2014;23(2):195–204.
19. Zhang Z, Wang Z, Li X, et al. Gene therapy in pain management: a review of progress and future prospects. Front Neurosci. 2020;14:606386.
20. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5):329–40.
21. Wang Y, Wang Z, Zhang J, et al. CRISPR/Cas9 gene editing: a promising therapeutic approach for neuropathic pain. Neurosci Bull. 2021;37(1):7–18.
22. Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70(2):207–12.
23. Kumar A, Lim S, Kim HJ, et al. Gene therapy for chronic pain: progress and challenges. Mol Pain. 2021;17:17448069211029150.
24. Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases:

The Neuromodulation Appropriateness Consensus Committee. Neuromodulation. 2014;17(6):515–50.
25. Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness. J Pain. 2003;4(3):109–21.
26. Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain. Am Psychol. 2014;69(2):153–66.
27. Vickers AJ, Linde K. Acupuncture for chronic pain. JAMA. 2014;311(9):955–6.
28. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2D6 and codeine therapy. Clin Pharmacol Ther. 2012;91(2):321–6.
29. Matic M, de Wildt SN, Tibboel D, et al. Pharmacogenetics of drug-metabolizing enzymes and transporters in the treatment of pain in children. Front Pharmacol. 2017;8:27.
30. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease: implications for personalized medicine. Pharmacol Rev. 2013;65(3):987–1009.
31. Davis MP. The emerging role of pharmacogenomics in pain management. Support Care Cancer. 2007;15(6):591–600.
32. Schmid RL, Sandler AN, Katz J. Use and efficacy of perioperative analgesic techniques in orthopedic surgery: a critical review. Anesthesiology. 1995;82(1):101–24.

1

Dr. Sridevi Pingali
Professor and Head, Department of Pharmaceutical Analysis,
Sri Venkateshwara college of Pharmacy, Madhapur, Hyderabad

2

Mrs. Kukkala Prasanna
Assistant professor, Department of Pharmaceutics,
Anurag pharmacy college, Ananthagiri, Kodad,
Suryapet Dt, Telangana, 508206.